Physician profile
Christopher E Pray
NPI 1891014213
$392,111.29
in general payments reported to CMS, 2019-2025
28 companies · $181K in 2025
The $181K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $6,202 · 2021: $8,196 · 2022: $12K · 2023: $62K · 2024: $123K · 2025: $181K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $293K · Travel and Lodging: $45K · Consulting Fee: $20K · Food and Beverage: $8,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $292,511.00 |
| Travel and Lodging | $44,661.26 |
| Consulting Fee | $20,040.00 |
| Food and Beverage | $8,406.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $291,274.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $45,930.38 | 2019-2025 | Wainua, Farxiga |
| Bridgebio Pharma, INC. | $26,837.02 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $17,005.21 | 2020-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $6,825.81 | 2019-2025 | Amvuttra, Onpattro |
| Edwards Lifesciences Corporation | $2,067.52 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $543.18 | 2020-2025 | Mitraclip, Confirm Rx |
| Novartis Pharmaceuticals Corporation | $291.66 | 2019-2025 | |
| Cvrx, INC. | $196.79 | 2022-2023 | Barostim Neo System |
| Boston Scientific Corporation | $166.55 | 2019-2021 | |
| Atricure, INC. | $123.46 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $112.85 | 2019-2021 | |
| Medtronic, INC. | $108.88 | 2023-2025 | Corevalve Evolut R |
| Kiniksa Pharmaceuticals, Ltd. | $96.39 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $94.93 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $76.44 | 2024-2025 | Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $60.88 | 2021-2024 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $47.22 | 2019 | |
| Amgen INC. | $39.19 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $34.49 | 2024 | |
| Esperion Therapeutics, INC. | $32.08 | 2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.67 | 2022-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $29.27 | 2019 | |
| Irhythm Technologies, INC. | $20.55 | 2024 | Zio Monitor, Zio Xt Patch |
| Akcea Therapeutics, INC. | $18.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.63 | 2024 | Jardiance |
| Amarin Pharma, INC. | $16.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Pray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.